<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526174</url>
  </required_header>
  <id_info>
    <org_study_id>HRI-002</org_study_id>
    <secondary_id>TNFalpha</secondary_id>
    <nct_id>NCT01526174</nct_id>
  </id_info>
  <brief_title>Intratympanic Injection for Autoimmune Inner Ear Disease</brief_title>
  <acronym>AIED</acronym>
  <official_title>Safety and Efficacy of Intratympanically Delivered Golimumab for Stabilization of Hearing in Patients With Autoimmune Inner Ear Disease: An Open-label Proof-of-concept Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>House Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Services, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>House Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to conduct an open-label intratympanic injection proof-of-concept
      trial of golimumab, a TNF-alpha inhibitor, assessing for hearing loss progression in patients
      with autoimmune inner ear disease (AIED). This specific aim will be achieved using a two-arm
      approach. First, the investigators propose to dose 3 individual subjects with a single
      intratympanic injection of golimumab and follow each for 30 days, closely examining them for
      adverse events. If there are no serious adverse events, with FDA approval, the investigators
      propose to dose 14 subjects, each with 4 intratympanic injections of golimumab.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    House Research no longer conducting research.
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Serious Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pure-tone threshold change</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in pure-tone threshold from baseline to 6 week after initiation of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Autoimmune Inner Ear Disease</condition>
  <arm_group>
    <arm_group_label>First Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine safety of intratympanic injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efficacy evaluation of 4 intratympanic injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <description>Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections</description>
    <arm_group_label>First Arm</arm_group_label>
    <arm_group_label>Second Arm</arm_group_label>
    <other_name>Simponi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of autoimmune inner ear disease (AIED) by the principal investigator

          -  Idiopathic, bilateral sensorineural hearing loss

          -  History of, or audiograms showing, rapid progression of hearing loss

          -  Bilateral loss of at least 30 dB in one or more frequencies (0.25 - 6 kHz)

          -  Hearing responsive on high-dose oral steroids and steroid-dependent, as determined by
             history and the principal investigator. The subject can be taking oral steroid, at the
             maintenance level, if enrolled in the First Arm and, if enrolled in the Second Arm,
             will begin taper after the first injection.

          -  Provided written informed consent for participation in the clinical study

        Exclusion Criteria:

          -  Positive MRI for vestibular schwannoma

          -  Positive FTA (syphilis)

          -  Significant middle ear disease (e.g., otitis media)

          -  Positive blood test for Lyme disease

          -  Positive tuberculosis test

          -  Concurrent or past treatment or use of medications and/or substances known to cause
             ototoxicity(for example, aminoglycosides [e.g., gentamicin], cisplatin, loop
             diuretics, Yorgason et al., 2006)

          -  Known adverse reaction to golimumab, adalimumab, etanercept, infliximab, rituximab,
             ustekinumab, or other biologic immunomodulators

          -  Concurrent (within the past 3 months prior to enrollment) live viral intranasal
             vaccine (flu)

          -  Positive test for HIV

          -  Positive test for Hepatitis B and C

          -  Presence of a demyelinating disease, such as multiple sclerosis

          -  Women of childbearing potential only: Positive serum pregnancy test prior to the
             only/first injection

          -  Active infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Derebery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>House Research Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>October 10, 2013</last_update_submitted>
  <last_update_submitted_qc>October 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autoimmune</keyword>
  <keyword>hearing loss</keyword>
  <keyword>bilateral hearing loss</keyword>
  <keyword>steroid-dependent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ear Diseases</mesh_term>
    <mesh_term>Labyrinth Diseases</mesh_term>
    <mesh_term>Labyrinthitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

